News and Announcements
SUDA Investor Presentation
- Published February 26, 2016 9:54AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
25th February 2016, ASX Announcement
Overview
- SUDA (ASX: SUD) is a drug delivery company commercialising low-risk pharmaceuticals
- Extensive proprietary technology, expertise and knowhow in formulating and manufacturing oral sprays
- Multiple patent families covering approx. 300 widely-used drugs formulated into oral sprays
- SUDA’s first-in-class oral sprays have demonstrated meaningful advantages vs. standard-of-care tablets in multiple clinical studies
- Multiple oral sprays for large markets – insomnia, malaria, migraine, erectile dysfunction, chemo-induced nausea
Oro-mucosal delivery | Better patient experience
- Oral mucosa is the lining of the mouth, richly supplied by blood vessels
- Oral cavity is ideal for systematic therapy, avoids metabolism in the gut
- Unique advantages of oral sprays compared to tablets
To view the full Investor Presentation, please click here.
Company Updates
Capital Is Flowing – Just Not to Everyone: Inside Australia’s $1.8 Billion Q1 2026
Australia’s startup ecosystem opened 2026 with a number that demanded attention. In the first three months of the year, $1.8 billion was raised across 81 venture deals and 26 accelerator rounds. That makes Q1 2026 the strongest start to a year since the 2022 boom, up 63% on Q1 2025, and more than double the […]
The control layer for the electrified home
THE MARKET SHIFT Australian households have been pulled into a real-time energy market they never knowingly signed up for. Flat electricity tariffs are disappearing. In their place: dynamic, time-of-use pricing that changes depending on when power is consumed. Electricity is now cheapest when solar floods the grid in the middle of the day — and […]
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
Backed By Leading Investment Groups and Family Offices
